Vaxart, Inc. Interest Expense
Vaxart, Inc. (VXRT) reported Interest Expense of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2022-02-24
- Vaxart, Inc. interest expense for the quarter ending 2019-12-31 was $27.00K, a 77.31% decline year-over-year.
- Vaxart, Inc. interest expense for the quarter ending 2019-09-30 was $84.00K, a 34.88% decline year-over-year.
- Vaxart, Inc. interest expense for the quarter ending 2019-06-30 was $97.00K, a 28.68% decline year-over-year.
- Vaxart, Inc. interest expense for the quarter ending 2019-03-31 was $107.00K, a 75.51% decline year-over-year.
- Vaxart, Inc. interest expense for fiscal 2021 was $0.00.
- Vaxart, Inc. interest expense for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Vaxart, Inc. interest expense for fiscal 2019 was $315.00K, a 61.63% decline from fiscal 2018.
- Vaxart, Inc. interest expense for fiscal 2018 was $821.00K, a 72.96% decline from fiscal 2017.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-24 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-02-24 | |||
| 2019-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $111.00K derived: sum of 2 quarters · filed 2022-02-24 | $208.00K derived: sum of 3 quarters · filed 2022-02-24 | $315.00K 10-K · filed 2022-02-24 |
| 2019-09-30 | $84.00K 10-Q · filed 2020-11-12 | $181.00K derived: sum of 2 quarters · filed 2020-11-12 | $288.00K 10-Q · filed 2020-11-12 | $407.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $97.00K 10-Q · filed 2020-08-06 | $204.00K 10-Q · filed 2020-08-06 | $323.00K derived: sum of 3 quarters · filed 2021-02-25 | $452.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $107.00K 10-Q · filed 2020-05-12 | $226.00K derived: sum of 2 quarters · filed 2021-02-25 | $355.00K derived: sum of 3 quarters · filed 2021-02-25 | $491.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $248.00K derived: sum of 2 quarters · filed 2021-02-25 | $384.00K derived: sum of 3 quarters · filed 2021-02-25 | $821.00K 10-K · filed 2021-02-25 |
| 2018-09-30 | $129.00K 10-Q · filed 2019-11-12 | $265.00K derived: sum of 2 quarters · filed 2019-11-12 | $702.00K 10-Q · filed 2019-11-12 | $1.47M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $136.00K 10-Q · filed 2019-08-08 | $573.00K 10-Q · filed 2019-08-08 | $1.34M derived: sum of 3 quarters · filed 2019-08-08 | $2.11M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $437.00K 10-Q · filed 2019-05-09 | $1.21M derived: sum of 2 quarters · filed 2019-05-09 | $1.97M derived: sum of 3 quarters · filed 2019-05-09 | $2.73M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $769.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06 | $1.54M derived: sum of 2 quarters · filed 2019-02-06 | $2.29M derived: sum of 3 quarters · filed 2019-02-06 | $3.04M 10-K · filed 2019-02-06 |
| 2017-09-30 | $768.00K 10-Q · filed 2018-11-13 | $1.52M derived: sum of 2 quarters · filed 2018-11-13 | $2.27M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $755.00K 10-Q · filed 2018-08-10 | $1.50M 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | $744.00K 10-Q · filed 2018-05-15 | |||
| 2010-12-25 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-14 | $23.00K derived: sum of 2 quarters · filed 2012-03-14 | $68.00K derived: sum of 3 quarters · filed 2012-03-14 | $210.00K 10-K · filed 2012-03-14 |
| 2010-09-25 | $13.00K 10-Q · filed 2011-11-02 | $58.00K derived: sum of 2 quarters · filed 2011-11-02 | $200.00K 10-Q · filed 2011-11-02 | |
| 2010-06-26 | $45.00K 10-Q · filed 2011-08-03 | $187.00K 10-Q · filed 2011-08-03 | ||
| 2009-12-26 | $1.07M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |